M
Merck & Co., Inc. (MRK)
NYQ – Real vaqt narxi. Valyuta: USD
112.37
+1.09 (0.98%)
Yopilishda: May 12, 2026, 4:00 PM EDT
111.56
-0.83 (-0.74%)
Bozor oldidan: May 13, 2026, 7:30 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
112.37
+1.09 (0.98%)
Yopilishda: May 12, 2026, 4:00 PM EDT
111.56
-0.83 (-0.74%)
Bozor oldidan: May 13, 2026, 7:30 AM EDT
Merck & Co., Inc. dunyo miqyosida sog'liqni saqlash kompaniyasi sifatida faoliyat yuritadi. U Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia va Janumet brendlari ostida turli sohalar uchun inson salomatligi uchun dori vositalarini taklif etadi. Kompaniya shuningdek, veterinariya dori vositalari, vaktsinalar hamda chorva mollari uchun Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox va Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brendlari ostida sog'liqni boshqarish bo'yicha yechimlar va xizmatlarni taqdim etadi; Allflex Livestock Intelligence yechimlari; hamda uy hayvonlari uchun Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare va Home Again brendlari ostidagi mahsulotlarni taklif etadi. U Daiichi Sankyo kompaniyasining uchta derukstekan ADC nomzodlari uchun ishlab chiqish va tijoratlashtirish bo'yicha kelishuvga ega; AstraZeneca PLC bilan AstraZeneca kompaniyasining ko'p turdagi saraton kasalliklari uchun mo'ljallangan Lynparza mahsulotlarini birgalikda ishlab chiqish va tijoratlashtirish bo'yicha hamkorlik; LaNova kompaniyasidan yangi tadqiqot ostidagi PD-1/VEGF bispesifik antitelasi LM-299ni ishlab chiqish, ishlab chiqarish va tijoratlashtirish litsenziyasi; hamda Eisai Co., Ltd., Bayer AG va Ridgeback Biotherapeutics LP, shuningdek Moderna, Inc. kompaniyalari bilan hamkorlik shartnomasi tuzgan. Merck & Co., Inc. Infinimmune, Inc. bilan birgalikda bir nechta terapevtik maqsadlarga qarshi antitelalarni kashf qilish va ishlab chiqish bo'yicha strategik hamkorlikni yo'lga qo'ygan. Kompaniya 1891-yilda tashkil etilgan va Nyu-Jersi shtatining Rahway shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Dean Y. Li M.D., Ph.D. | Executive VP & President of Merck Research Laboratories |
| Mr. Chirfi Guindo | Executive Vice President of Strategic Access, Policy & Communications |
| Mr. Dalton E. Smart III | Senior VP of Finance, Principal Accounting Officer & Global Controller |
| Mr. David Michael Williams | Executive VP and Chief Information & Digital Officer |
| Mr. Peter Dannenbaum | Vice President of Investor Relations |
| Mr. Richard R. DeLuca Jr. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | SC TO-T/A | d81127dsctota.htm |
| 2026-05-04 | 10-Q | mrk-20260331.htm |
| 2026-04-30 | 8-K | tm2612241d1_8k.htm |
| 2026-04-24 | SC TO-T/A | d114406dsctota.htm |
| 2026-04-08 | DEF 14A | d85708ddef14a.htm |
| 2026-04-07 | SC TO-T | d43298dsctot.htm |
| 2026-02-24 | 10-K | mrk-20251231.htm |
| 2026-02-03 | 8-K | tm264564d1_8k.htm |
| 2026-01-07 | SC TO-T/A | d55695dsctota.htm |
| 2025-12-04 | 8-K | mrk-20251204.htm |
| Executive VP & President of Merck Animal Health |
| Mr. Robert M. Davis J.D. | Chairman, President & CEO |
| Ms. Betty D. Larson | Executive VP & Chief Human Resources Officer |
| Ms. Caroline A. Litchfield | Executive VP & CFO |
| Ms. Jennifer L. Zachary J.D. | Executive VP & General Counsel |